drugset / Trial / NCT00191009

Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease

NCT00191009

Phase 2/3 Completed 124 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will compare atomoxetine to placebo when taken with current standard Alzheimer's Disease medications. The treatment will take approximately 6 months and it is hypothesized atomoxetine will significantly improve cognitive performance as compared to placebo.

Timeline

Start
2003-10
Primary completion
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified

Indications